Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13

Nephrology Dialysis Transplantation

Volumn 32, Issue 4, 2017, Pages 692-698

  Birnie, Kate ^a   Caskey, Fergus ^a,b   Ben Shlomo, Yoav ^a   Sterne, Jonathan A C ^a   Gilg, Julie ^b   Nitsch, Dorothea ^c   Tomson, Charles ^d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d FREEMAN HOSPITAL   (United Kingdom)

Author keywords

anaemia management; erythropoiesis stimulating agents; ESA; haemodialysis; haemoglobin

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED KINGDOM; ADVERSE EFFECTS; BLOOD; DOSE RESPONSE; DRUG EFFECTS; ERYTHROPOIESIS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; REGISTER; TIME FACTOR;

AGED; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIESIS; FEMALE; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RENAL DIALYSIS; TIME FACTORS;

EID: 85019167025     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw043     Document Type: Article

References (26)

1. Rao A, Casula A, Castledine C. UK Renal Registry 17th Annual Report: Chapter 2 UK Renal Replacement Therapy Prevalence in 2013: national and centre-specific analyses. Nephron 2015; 129 (Suppl 1): 31-56
2. Mikhail A, Shrivastava R, Richardson D. Clinical Practice Guidelines. Anaemia of CKD, 5th edn. http://www.renal.org/guidelines (1 July 2015, date last accessed). UK Renal Association, 2010
3. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl JMed 1998; 339: 584-590
4. FDA Drug Safety Communication: modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm2011 (11 August 2015, date last accessed)
5. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012; 82: 235-241
6. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
7. PfefferMA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. NEngl JMed 2009; 361: 2019-2032
8. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease.NEngl JMed 2006; 355: 2085-2098
9. Levin A, Djurdjev O, Duncan J et al. Haemoglobin at time of referral prior to dialysis predicts survival: An association of haemoglobin with long-term outcomes. Nephrol Dial Transplant 2006; 21: 370-377
10. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J AmSoc Nephrol 2006; 17: 1181-1191
11. Macdougall IC, Tomson CR, SteenkampM et al. Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: An observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up.Nephrol Dial Transplant 2010; 25: 914-919
12. Standards and Audit Subcommittee of the Renal Association. Treatment of Adults and Children with Renal Failure. Standards and AuditMeasures, 3rd edn. London: Royal College of Physicians, 2002
13. Cassidy M, Richardson D, Jones C. Clinical Practice Guidelines. Module 2: Complications, 4th edn. http://www.renal.org/guidelines (1 July 2015, date last accessed). UK Renal Association, 2007
14. Ansell D, Tomson CR. UK Renal Registry 11th Annual Report (December 2008): Chapter 15 The UK Renal Registry, UKRR database, validation and methodology. Nephron Clin Pract 2009; 111 (Suppl 1): c277-c285
15. UK Renal Registry 17th Annual Report: Appendices. Nephron 2015; 129 (Suppl 1): 267-322
16. National Institute for Health and Care Excellence. AnaemiaManagement in People with Chronic Kidney Disease. NICE Clinical Guideline 114. http:// www.nice.org.uk/guidance/cg114. NICE, 2011.
17. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279-335
18. National Institute for Health and Care Excellence. AnaemiaManagement in People with Chronic Kidney Disease. NICE Clinical Guideline 39. https:// www.nice.org.uk/guidance/cg39. NICE, 2006.
19. Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis. Am J Nephrol 2014; 39: 130-141
20. Regidor D, McClellan WM, Kewalramani R et al. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Nephrol Dial Transplant 2011; 26: 1583-1591
21. Freburger JK, Ng LJ, Bradbury BD et al. Changing patterns of anemia management in US hemodialysis patients. Am JMed 2012; 125: 906-914.e9
22. Fuller DS, Pisoni RL, Bieber BA et al. The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J KidneyDis 2013; 62: 1213-1216
23. Karaboyas A, Zee J,Morgenstern H et al. Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol 2015; 10: 1814-1821
24. Kleophas W, Karaboyas A, Li Y et al. Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs. Kidney Int 2013; 84: 578-584
25. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: A systematic review of rigorous evaluations. Lancet 1993; 342: 1317-1322
26. Grol R, Dalhuijsen J, Thomas S et al. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ 1998; 317: 858-861